Ablation of CCL2/CCR2 axis via neutralizing monoclonal antibodies (mAbs), antisense RNA or genetic manipulation has been shown to inhibit the development of tumor progression and metastasis in bone marrow, breast, liver and lung cancers [22, 23, 26, 27]. Here, CCL2 is linked to neoplasm.